Status:
UNKNOWN
ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.
Lead Sponsor:
Shanghai Changzheng Hospital
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
This clinical trial aims to evaluate the efficacy, safety of ALK inhibitor in Metastatic Colorectal Cancer Patients with ALK mutation.
Eligibility Criteria
Inclusion
- Patients should be histologically diagnosed with metastatic colorectal cancer or postoperative recurrence; Patients with ALK mutation(including mutation, fusion, rearrangements ); Patients have measurable lesions; Patients are not available for targeted therapy or patients refuse to receive targeted therapy afer second-line treatment; Over 3 weeks after radiotherapy and the radiotherapy focus was not be measured; Age should be 18-25 years; Performance status should be 0-2; Life expectancy should be more than 12 weeks;
Exclusion
- Patients underwented major surgery or severe trauma within 4 weeks; Patients allergiced to experimental drugs; Patient ready to give birth or who is pregnant; Patients with brain metastases; Patients with chemotherapy contraindication; Patients could not tolerate chemotherapy; Patients have secondary primary tumor.
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03792568
Start Date
March 1 2019
End Date
March 1 2021
Last Update
February 15 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China, 200433
2
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China, 200433
3
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China, 200433